Mr Market is far smarter and infinitely more experienced than average HC punter.
CUV holders seem totally incapable of understanding that orphan drugs (<200,000 patients) - like Scenesse - have much lower regulatory standards than normal. So existing FDA, TGA etc approval for EPP actually means very little.
The market simply doesn't believe the hype about new indications. Fifty years of research on alpha-melanocortin analogues has only produced two obscure orphan drugs and massive number of failures. Virtually ever other drug has has failed Phase I or Phase 2 trials.
Ann: Becoming a substantial holder, page-7
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |